Ranger Investment Management L.P. Lowers Stock Position in LeMaitre Vascular, Inc. $LMAT

Ranger Investment Management L.P. trimmed its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 25.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 385,800 shares of the medical instruments supplier’s stock after selling 128,274 shares during the period. LeMaitre Vascular makes up about 2.4% of Ranger Investment Management L.P.’s investment portfolio, making the stock its 6th biggest position. Ranger Investment Management L.P. owned 1.70% of LeMaitre Vascular worth $33,761,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Geneva Capital Management LLC boosted its holdings in LeMaitre Vascular by 6.0% during the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock valued at $76,010,000 after purchasing an additional 51,489 shares in the last quarter. Congress Asset Management Co. raised its stake in LeMaitre Vascular by 2.7% during the third quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock worth $60,580,000 after acquiring an additional 18,298 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of LeMaitre Vascular by 52.7% during the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after acquiring an additional 211,280 shares during the period. Geode Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 3.0% in the 2nd quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier’s stock worth $43,174,000 after purchasing an additional 15,036 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its position in shares of LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock worth $25,293,000 after purchasing an additional 19,447 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 2.3%

Shares of LMAT opened at $88.82 on Friday. The stock’s fifty day simple moving average is $84.44 and its 200-day simple moving average is $87.61. The firm has a market capitalization of $2.02 billion, a PE ratio of 37.87, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $105.55. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.05. The firm had revenue of $61.05 million during the quarter, compared to analysts’ expectations of $62.18 million. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.49 EPS. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on LMAT. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Wells Fargo & Company decreased their price target on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Roth Mkm restated a “buy” rating and set a $108.00 target price on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $100.20.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.